February 05, 2022
Chiesi Farmaceutici S.p.A. (Chiesi Group), the international research-focused pharmaceutical and healthcare group, announced it has entered into an agreement with Allinaire Therapeutic, LLC, a Harrington Project company founded by BioMotiv. Chiesi will acquire the world-wide rights to monoclonal antibodies (mAbs) against endothelial monocyte-activating polypeptide II (EMAP II) for treatment of Pulmonary Artery Hypertension (PAH). Harrington Discovery Institute provided the initial grant funding and therapeutic development services to Irina Petrache, MD, 2014 Harrington Scholar-Innovator at Indiana University and National Jewish Health.
"I received not only funding from Harrington Discovery Institute, but also a lot of help in how to take our approach, which is very academic, into a commercially appealing and valuable product."
- Irina Petrache, MD
Click here to read the full article on Chiesi's website
2014 Harrington Scholar-Innovator